1. Home
  2. JAGX vs INDP Comparison

JAGX vs INDP Comparison

Compare JAGX & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JAGX
  • INDP
  • Stock Information
  • Founded
  • JAGX 2013
  • INDP 2000
  • Country
  • JAGX United States
  • INDP United States
  • Employees
  • JAGX N/A
  • INDP N/A
  • Industry
  • JAGX Biotechnology: Pharmaceutical Preparations
  • INDP Biotechnology: Pharmaceutical Preparations
  • Sector
  • JAGX Health Care
  • INDP Health Care
  • Exchange
  • JAGX Nasdaq
  • INDP Nasdaq
  • Market Cap
  • JAGX 3.9M
  • INDP 4.0M
  • IPO Year
  • JAGX N/A
  • INDP N/A
  • Fundamental
  • Price
  • JAGX $1.71
  • INDP $2.61
  • Analyst Decision
  • JAGX Strong Buy
  • INDP Strong Buy
  • Analyst Count
  • JAGX 1
  • INDP 1
  • Target Price
  • JAGX $60.00
  • INDP $140.00
  • AVG Volume (30 Days)
  • JAGX 114.8K
  • INDP 114.1K
  • Earning Date
  • JAGX 11-14-2025
  • INDP 11-07-2025
  • Dividend Yield
  • JAGX N/A
  • INDP N/A
  • EPS Growth
  • JAGX N/A
  • INDP N/A
  • EPS
  • JAGX N/A
  • INDP N/A
  • Revenue
  • JAGX $11,810,000.00
  • INDP N/A
  • Revenue This Year
  • JAGX $22.41
  • INDP N/A
  • Revenue Next Year
  • JAGX $30.00
  • INDP N/A
  • P/E Ratio
  • JAGX N/A
  • INDP N/A
  • Revenue Growth
  • JAGX 15.96
  • INDP N/A
  • 52 Week Low
  • JAGX $1.57
  • INDP $2.22
  • 52 Week High
  • JAGX $33.25
  • INDP $47.60
  • Technical
  • Relative Strength Index (RSI)
  • JAGX 36.00
  • INDP 33.38
  • Support Level
  • JAGX $1.77
  • INDP $2.50
  • Resistance Level
  • JAGX $2.00
  • INDP $3.76
  • Average True Range (ATR)
  • JAGX 0.13
  • INDP 0.26
  • MACD
  • JAGX -0.04
  • INDP -0.08
  • Stochastic Oscillator
  • JAGX 9.09
  • INDP 7.04

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Share on Social Networks: